Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
I know the journalist.....it’s true. Look back to his other articles on the LFD sovereign resource consortium. BBI / Abingdon / Avacta is one of the teams. In October he stated our consortium with government help was aiming at 7 million a day. So we start at 2 and if he’s right 7 million a day is the mid term target. Great investment everyone we got it right. So sit back and enjoy
Hypermarlin
The sovereign resource rumour and now fact has been backed up over the last 5 months by various DHSC procurement announcements. The question was what were they doing with the resource machinery well now we know part of the answer. They were buying to loan out to some of the syndicate of factories. However unlikely to be full answer. Clear as mud!
Unprecedented / Benbenben
Thanks for facts & possible conclusions. The only bona fide fact I can add to the discussion is I know there was never any original intention to duplicate the original tech transfer from Avacta to BBI with concurrent tech transfer to Abingdon. This was considered duplication of work and Abingdon were to wait to receive completed test ‘package’ from BBI. However from at least early October Avacta were working with Abingdon on a separate project I have no information on what it was. I don’t know what the relationship is now but Alastair back in August was the main instigator behind choosing which companies were put together for the government’s LFD aspirations.
On Aim risk/reward is often the name of the game. Most Aim shares are under researched and Abingdon has all the makings of being a perfect opportunity for the retail investor. Due to my stated belief in the growth of the UK diagnostic resource base (and Avacta) I thought the risk/reward looked acceptable and took my initial position last month, missing the recent fall??. Going forward we are going to get government leaks, rns announcements and leaks/announcements from connected consortium companies changing the risk/reward equation. Hopefully this will give many retail investors the chance to invest or add in advance of the main market. Potentially the negative press is an opportunity. Suggest this should be on everyone’s watch list
Confess I’m a little mystified by retail investors reaction to this share. I guess if you don’t believe there is a government backed consortium in place and government orders for as many LFDs as they can manufacture fast approaching on the horizon then I wouldn’t invest either as too high risk. However if you do believe the mounting positive information then Abingdon is now undoubtedly the cheapest option short/medium and probably long term.
That Beret is the $1,000 dollar question, no ce mark for Avacta or a n other known supplier. I am a long term shareholder in Avacta and have only recently invested here. I’ve watched the rumour of sovereign LFD production grow over the last 4 months. The confirmation information has been steadily growing till Boris finally confirmed it 100% last week. So far a billion plus has been spent on importing LFDs, now that money and more is heading into the UK industry. Abingdon is at the heart of that and I believe will sell every test they can make. Personally I’m sure it’s Avacta’s but if it isn’t the government will ensure that production capacity is filled.
Previous Huffington Post article looked well resourced. They put Mologic/GAD/Omega together as 1 part of the government sovereign LFD production. Now confirmed (well almost) as correct. Abingdon/BBI & Avacta were named as the second part and would logically be able to supply a larger volume.
Last part of ft article states as fact....the health department said we now have the largest diagnostic network in UK history and our procurement strategy for testing ensures the uk has supplies needed to support both the existing symptomatic testing and the expanding programme of assymptomatic testing being carried out. ......So according to the ft health department quote the uk sovereign resource now has capacity for somewhere between 100-200 million tests per month.
What Huff post said makes sense there are 2 ‘teams Mologic/Gad & Omega producing Mologic and now Surescreen LFDs. Second team is BBI, Abingdon and I hope only Avacta. Both teams have been built up by the government to have ?? Capacity. Government have been quoted as 150/200 million tests per month. Work place testing etc etc would seem to confirm that figure
Just doing random slightly desperate google search on Adeptrix/BAMS/Avacta and came up with Shares magazine update tonight on Adeptrix COVID test with no extra info other than July rns. Anyone any idea what that’s about don’t ever read the mag.
JFI There will be a new FDA Virtual Town Hall ‘Webinar’ for COVID-19 test developers out tomorrow. I thought the last couple were well worth a listen, recording and transcript are available almost immediately.
I haven’t posted for about a year. I lost about 95% of my investment 5 years ago. When I ‘discussed’ my losses with Andrew and his misleading statements he looked me straight in the eyes and said that’s the problem with you lot who’ve lost your money you won’t keep putting new money in. I need new investors. I can’t say what I really think about his honesty as it will be deleted. But buyer beware unless you are trading this share avoid. As Mont Python said This is not a share for buying....it’s a share for laying down and avoiding. Please invest anywhere except here.
Rusty
I don’t post here very often but have known Alastair for a long time now. I have always found him to be a man of deep integrity but I too have found some of his recent bullish statements a bit concerning as they have in my opinion been out of character. So either he is incredibly confident about Affimers/PreCISION and consequently Avacta’s short / mid term success or he has completely lost the plot. I still give him the benefit of doubt and believe he will deliver the success he promises. For the record I don’t think he looked nervous but did look exhausted. OC
If and of course it is still a big if there is a big pharma deal given the current COVID scenario it would now be the quickest way to get Affimers into phase1 clinical trials and the massive milestone of safe in human data
I thought the panel discussion last night confirmed the ‘unbelievable’ 30% failure rate in the current laboratory pcr tests and the various bottlenecks to hamper the increase and speeding up of COVID testing. The BAMS test should be the quicker to market and may just be the dark horse.
The agreement signed in April to cut a long story short is to open up Abingdon’s ‘cutting edge’ technology for turning a smart phone into a lateral flow test reader and recording results in real time to a wider product / design base. Just google DCN Abingdon agreement. DCN website has a lot more info.